Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)
Completed
- Conditions
- Diffuse Large B-cell Lymphoma
- Registration Number
- NCT00754117
- Lead Sponsor
- Weill Medical College of Cornell University
- Brief Summary
Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Patients must have histologically or cytologically confirmed diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma
- Patients must have received no prior anti-lymphoma therapy.
- Age >18 years.
- Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
- Patients who have known HIV infection.
- Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evaluating the predictive value of a positive PET scan early in the course of standard chemotherapy after 2 cycles of chemotherapy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Weill Cornell Medical College
🇺🇸New York, New York, United States